What we do
Leveraging our core strengths in scaling, production, and bioprocessing, we build businesses and find new ways to support access to medicines and promote sustainability.
Through entrepreneurship and technology-driven affordability, we address the needs of the entire health value chain.
Who we are - History
Making biologics available & affordable to all through technology innovation
Key figures
- 2013 Incorporation Date
- 5 companies 1 Group with 4 affiliates
- 15.000m2 New offices in Jumet
- 350+ Dedicated people
Latest News
Belgium: EIB boosts innovative biotech company Univercells with €30…
• €30 million loan agreement for a new COVID-19 vaccine manufacturing facility in Wallonia (Belgium) and for the co-development of a pipelin…
Univercells unveils new brand identity and logo
Brussels, Belgium, June 30, 2021 Univercells S.A. (the “Company”) announces a rebranding of its visual identity and update of its mission t…
Univercells and Exothera announce Thibault Jonckheere as NEW CEO of…
Univercells S.A. (“Univercells”) and Exothera S.A. (the “Company”) are pleased to announce that effective June 1, 2021, Thibault Jonckheere…
Codagenix and Univercells Announce Research Collaboration on Undiscl…
Partnership will leverage companies’ core technologies in vaccine development and viral vaccine manufacturing Codagenix Inc., a clinical-st…